[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568653":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":47,"slug":19,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":19,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":19,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Affiliated Hospital of Jiangnan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-FAPI-JNU","EXPERIMENTAL","68Ga-FAPI-JNU is administered through a superficial vein on the back of the hand. A PET\u002FCT scan was performed approximately 1 hour after injection",[13],"Drug: 68Ga-FAPI-JNU",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"chunjing Yu","CONTACT","15312238622","ycj_wxd1978@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Affiated Hospital of Jiangnan University","RECRUITING","Wuxi","Jiangsu","214000","China",{"type":35,"coordinates":36},"Point",[37,38],120.28857,31.56887,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":19,"email":43},"Chunjing Yu","ycjwxd1978@jiangnan.edu.cn",{"type":45,"investigatorFullName":42,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Director","100568653",false,"NCT06684028","PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors","Inclusion Criteria:\n\n1. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;\n2. Age 18-85 years old, male or female;\n3. Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;\n4. ECOG score is 0-3 points;\n\nExclusion Criteria:\n\n1. Patients with a history or allergic constitution to any component of the developer, including alcohol;\n2. pregnant or lactating women;\n3. Patients with mental illness or related history;\n4. Patients who cannot or cannot undergo a PET\u002FCT scan;","ALL","18 Years","85 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60],"NA","To investigate the biological distribution of a new tracer 68Ga-FAPI-JNU in the primary, metastatic and normal tissues of patients with malignant tumors, and to evaluate the biological distribution of 68GA-FAPI-JNU with standardized uptake values.",[63,64],"Cancer","Solid Malignancies",[66,67,68,69],"FAP","FAPI","PET","cancer","2025-01-18",{"date":72,"type":73},"2025-01-22","ACTUAL",{"date":75,"type":73},"2023-07-12",{"date":77,"type":57},"2025-07-31",{"name":5,"class":6},1]